Sader H S, Rhomberg P R, Jones R N
JMI Laboratories, North Liberty, Iowa, USA.
J Chemother. 2005 Dec;17(6):622-7. doi: 10.1179/joc.2005.17.6.622.
We evaluate the antimicrobial interactions between aztreonam and selected beta-lactams when tested against metallo-beta-lactamase (MbetaL)-producing clinical strains. Ten Pseudomonsa aeruginosa strains, including nine MbetaL-producers (IMP-1, -2, -13, -16, VIM-1, -2, -7, SPM-1 and GIM-1) and five Acinetobacter baumannii strains, including three MbetaL-producers (IMP-1 and -2) were tested using time kill/bactericidal activity methods. Aztreonam at 4, 8 and 16 mg/L was combined with four other beta-lactam antimicrobials (cefepime, ceftazidime, meropenem and piperacillin/tazobactam or ampicillin/sulbactam), each tested at the recognized susceptible breakpoint concentration. Enhanced activity (synergism or additive effect) was observed with four P. aeruginosa strains (IMP-16, VIM-2, SPM-1 and GIM-1 containing strains) and four A. baumannii strains, while antagonism was observed with two P. aeruginosa (IMP-16 and SPM-1-producing strains) and one A. baumannii (non-MbetaL) strain. All other strains showed indifferent interaction (variation of +/- 1 log10 CFU/ml) with any combination evaluated.
我们采用时间杀菌活性方法,对氨曲南与选定的β-内酰胺类药物针对产金属β-内酰胺酶(MβL)的临床菌株进行抗菌相互作用评估。测试了10株铜绿假单胞菌菌株,包括9株产MβL菌株(IMP-1、-2、-13、-16、VIM-1、-2、-7、SPM-1和GIM-1),以及5株鲍曼不动杆菌菌株,包括3株产MβL菌株(IMP-1和-2)。将4、8和16mg/L的氨曲南与其他4种β-内酰胺类抗菌药物(头孢吡肟、头孢他啶、美罗培南和哌拉西林/他唑巴坦或氨苄西林/舒巴坦)联合使用,每种药物均在公认的敏感断点浓度下进行测试。在4株铜绿假单胞菌菌株(含IMP-16、VIM-2、SPM-1和GIM-1的菌株)和4株鲍曼不动杆菌菌株中观察到增强活性(协同或相加效应),而在2株铜绿假单胞菌(产IMP-16和SPM-1的菌株)和1株鲍曼不动杆菌(非MβL)菌株中观察到拮抗作用。所有其他菌株与所评估的任何组合均表现为无关相互作用(±1 log10 CFU/ml的变化)。